[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:multiple-system-atrophy":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":220,"states":221},"Multiple System Atrophy",34,27,[8,16,22,28,35,40,46,52,58,64,71,77,83,90,96,102,108,114,120,126,132,138,144,150,156,162,168,175,182,188,195,201,207,213],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07197866","An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy",[12],"Phase 2","RECRUITING","2026-08-26T02:17:53.433613Z","2026-05-05T02:43:28.837397Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06848231","A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy",[12],"2026-08-03T02:53:48.712822Z","2026-05-05T02:43:28.826293Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT06568237","A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy",[12],"2026-08-26T02:16:09.452956Z","2026-05-05T02:43:28.529506Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":33,"content_modified":34},"NCT06683365","Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies",[32],"Phase 1","2026-08-26T02:15:10.362237Z","2026-05-05T02:43:28.215432Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":33,"content_modified":39},"NCT06868628","A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)",[12],"2026-04-29T02:57:57.141467Z",{"nct_id":41,"title":42,"phases":43,"status":13,"updated_at":44,"content_modified":45},"NCT03312556","Treatment of Supine Hypertension in Autonomic Failure (CPAP)",[],"2026-08-26T02:18:23.582895Z","2026-05-05T02:43:28.367642Z",{"nct_id":47,"title":48,"phases":49,"status":13,"updated_at":50,"content_modified":51},"NCT03042988","Overnight Trials With Heat Stress in Autonomic Failure Patients With Supine Hypertension",[],"2026-08-26T02:16:16.169331Z","2026-05-05T02:43:28.204153Z",{"nct_id":53,"title":54,"phases":55,"status":13,"updated_at":56,"content_modified":57},"NCT05489575","CPAP for the Treatment of Supine Hypertension",[],"2026-08-26T02:15:24.145250Z","2026-05-05T02:43:29.495886Z",{"nct_id":59,"title":60,"phases":61,"status":13,"updated_at":62,"content_modified":63},"NCT02795052","Neurologic Stem Cell Treatment Study",[],"2026-08-26T02:15:11.740957Z","2026-04-29T02:57:57.086071Z",{"nct_id":65,"title":66,"phases":67,"status":13,"updated_at":69,"content_modified":70},"NCT06303921","Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503",[68],"Early Phase 1","2026-08-26T02:18:11.042248Z","2026-05-05T02:43:29.498259Z",{"nct_id":72,"title":73,"phases":74,"status":13,"updated_at":75,"content_modified":76},"NCT06032026","Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15",[68],"2026-08-26T02:17:06.985283Z","2026-05-05T02:43:29.328908Z",{"nct_id":78,"title":79,"phases":80,"status":13,"updated_at":81,"content_modified":82},"NCT06083467","CW2IP2: Imaging and Diagnostic Assessments",[],"2026-08-26T02:17:23.750999Z","2026-05-05T02:43:27.262275Z",{"nct_id":84,"title":85,"phases":86,"status":13,"updated_at":88,"content_modified":89},"NCT03143374","PET Tau - Neurodegenerative Disease Imaging",[87],"Phase 2\u002FPhase 3","2026-08-26T02:16:03.788292Z","2026-05-05T02:43:28.343973Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT07640555","Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies",[68],"2026-08-26T02:18:46.137046Z","2026-06-14T18:39:22.259538Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT03811808","Multiple System Atrophy Multidisciplinary Clinic",[],"2026-08-26T02:15:33.331531Z","2026-05-13T02:55:06.176715Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT06647641","The CurePSP Genetics Program",[],"2026-08-26T02:16:21.385056Z","2026-05-13T02:55:06.558839Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT05347407","Parkinson's Disease Biomarkers in Nerve Cells in the Gut",[],"2026-08-26T02:17:59.904383Z","2026-05-13T02:55:06.301139Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT03872102","Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging",[],"2026-08-26T02:15:52.238965Z","2026-05-13T02:55:06.179692Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT06203106","NYSCF Scientific Discovery Biobank",[],"2026-08-26T02:15:57.572488Z","2026-05-13T02:55:06.425562Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":130,"content_modified":131},"NCT02194816","Modifiable Variables in Parkinsonism (MVP)",[],"2026-08-26T02:17:05.997056Z","2026-05-13T02:55:06.083137Z",{"nct_id":133,"title":134,"phases":135,"status":13,"updated_at":136,"content_modified":137},"NCT01793168","Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford",[],"2026-08-26T02:17:29.353236Z","2026-05-13T02:55:06.077983Z",{"nct_id":139,"title":140,"phases":141,"status":13,"updated_at":142,"content_modified":143},"NCT01799915","Natural History Study of Synucleinopathies",[],"2026-08-26T02:19:14.560989Z","2026-05-13T02:55:06.077141Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":148,"content_modified":149},"NCT06098612","PET Imaging Evaluation of [11C]SY08",[68],"2026-08-26T02:15:22.311223Z","2026-05-05T02:43:29.296692Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":154,"content_modified":155},"NCT04246437","[18F]F-DOPA Imaging in Patients With Autonomic Failure",[32],"2026-08-26T02:18:53.782384Z","2026-05-05T02:43:28.214049Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":160,"content_modified":161},"NCT04782830","Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms",[],"2026-08-26T02:15:51.395565Z","2026-05-05T02:43:27.679256Z",{"nct_id":163,"title":164,"phases":165,"status":13,"updated_at":166,"content_modified":167},"NCT02897063","Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure",[32],"2026-08-26T02:17:33.807405Z","2026-05-05T02:43:26.936793Z",{"nct_id":169,"title":170,"phases":171,"status":13,"updated_at":173,"content_modified":174},"NCT05357612","Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases",[172],"Phase 4","2026-08-26T02:18:17.007929Z","2026-05-05T02:43:27.661695Z",{"nct_id":176,"title":177,"phases":178,"status":179,"updated_at":180,"content_modified":181},"NCT04753320","Remote Monitoring in Progressive Supranuclear Palsy (PSP)",[],"NOT_YET_RECRUITING","2026-08-26T02:15:20.225313Z","2026-07-24T01:27:14.900280Z",{"nct_id":183,"title":184,"phases":185,"status":179,"updated_at":186,"content_modified":187},"NCT07646652","Alpha-synuclein Education and Disclosure in Individuals With Preclinical and Symptomatic Lewy Body Disease",[],"2026-08-26T02:16:47.762107Z","2026-06-16T05:54:07.903276Z",{"nct_id":189,"title":190,"phases":191,"status":192,"updated_at":193,"content_modified":194},"NCT07081841","AB-1005 Long-Term Follow-up Study",[],"ENROLLING_BY_INVITATION","2026-08-26T02:18:32.765187Z","2026-06-16T05:54:07.852787Z",{"nct_id":196,"title":197,"phases":198,"status":192,"updated_at":199,"content_modified":200},"NCT07148960","Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?",[172],"2026-08-26T02:16:42.787115Z","2026-06-16T05:54:07.865949Z",{"nct_id":202,"title":203,"phases":204,"status":192,"updated_at":205,"content_modified":206},"NCT04680130","Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders",[],"2026-08-26T02:15:56.561131Z","2026-07-05T18:42:10.712485Z",{"nct_id":208,"title":209,"phases":210,"status":192,"updated_at":211,"content_modified":212},"NCT05826457","North American Prodromal Synucleinopathy Consortium Stage 2",[],"2026-08-26T02:17:57.997171Z","2026-05-13T02:55:06.379597Z",{"nct_id":214,"title":215,"phases":216,"status":217,"updated_at":218,"content_modified":219},"NCT02994719","Gait Analysis in Neurological Disease",[],"ACTIVE_NOT_RECRUITING","2026-08-03T03:52:12.406209Z","2026-05-13T02:55:06.105137Z",[],[222,226,230,234,237,240,244,248,252,255],{"state":223,"count":224,"slug":225},"Tennessee",10,"tennessee",{"state":227,"count":228,"slug":229},"Massachusetts",9,"massachusetts",{"state":231,"count":232,"slug":233},"California",6,"california",{"state":235,"count":232,"slug":236},"New York","new-york",{"state":238,"count":232,"slug":239},"Pennsylvania","pennsylvania",{"state":241,"count":242,"slug":243},"Minnesota",5,"minnesota",{"state":245,"count":246,"slug":247},"Texas",4,"texas",{"state":249,"count":250,"slug":251},"Connecticut",3,"connecticut",{"state":253,"count":250,"slug":254},"Florida","florida",{"state":256,"count":250,"slug":257},"Washington","washington"]